

ASCOconnection.org

Stay Connected With Oncology Professionals Across the Globe

Sign up for FREE ASCO Connection Biweekly Digest



# JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology Log In Submit E-Alerts Subscribe

[OpenAthens/Shibboleth »](#)

MENU

Article Tools

GASTROINTESTINAL (COLORECTAL) CANCER

**Prolonged (PI) vs short-term irinotecan (STI) administration: The Martha trial—A SICOG (Southern Italy Cooperative Oncology Group) randomized phase III study in the first-line setting of metastatic colorectal cancer (mCRC) patients (pts).**

[Vincenzo Formica](#), [Maria Teresa Ionta](#), [Vessia Giacomo](#), [Luigi Maiorino](#), [Rossana Casaretti](#), [Donato Natale](#),

[Show More](#)

[Abstract Disclosures](#)

## Abstract

3552

**Background:** FOLFIRI+bevacizumab(B) is a standard first-line regimen for mCRC pts. It should be delivered until progression, though an early switch to a de-intensified maintenance regimen is often adopted because of toxicity. The MARTHA trial compared FOLOFIRI+B for 6 months(mo) followed by maintenance B monotherapy up to 12mo (PI arm) vs FOLOFIRI+B for 3mo followed by capecitabine+B for further 3mo followed by B monotherapy up

## OPTIONS & TOOLS

[Export Citation](#)

[Track Citation](#)

[Add To Favorites](#)

[Rights & Permissions](#)

## COMPANION ARTICLES

No companion articles

## ARTICLE CITATION

DOI:  
10.1200/JCO.2017.35.15\_suppl.3552  
*Journal of Clinical Oncology* 35, no. 15\_suppl  
(May 2017) 3552-3552.

## WHAT'S POPULAR

**Most Read**

**Most Cited**

[Minimal Residual Disease Assessed by Multiparameter Flow](#)

ASCO Education Es  
For Oncology Fellow

**For Every  
Fellow.  
Everywhere**

ASCO

Register Today

**Genitourinary  
Cancers Symp**

**February 8-10, 2018**  
Moscone West Building  
San Francisco, California

Early Registration Deadline  
January 3 at 11:59 PM (EST)